Open Label News Today

Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, ...

Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Les Ruthven addresses the difference between basing a medical system on clinical belief versus one based on scientific evidence.

Cheung shares his approach to using novel immunotherapies in IgAN to prevent infection.

Disease Landscape Insights equips healthcare pioneers with the tools to combat ringworm early stages, providing in-depth diagnostic, treatment, and market...

MELBOURNE, Australia, July 19, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814). The study is being conducted in patients with solid tumours expressing carbonic-anhydrase IX (CAIX), a...

CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to placebo at 24 weeks Clene plans to discuss the totality of the survival and time-to-event... | June 16, 2023

Expands pipeline with acquisition of new tri-specific antibodiesData readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023,...